- Home
- DFLI vs ADIL Comparison
DFLI vs ADIL Comparison
Compare DFLI & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DFLI | ADIL |
|---|---|---|
| Founded | 2020 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8M | 18.5M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | DFLI | ADIL |
|---|---|---|
| Price | $0.88 | $5.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.25 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 243.7K | 51.0K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,630,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $51.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.77 | N/A |
| 52 Week Low | $0.28 | $0.13 |
| 52 Week High | $5.15 | $7.20 |
Technical Indicators
Market Signals| Indicator | DFLI | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 28.61 | 45.98 |
| Support Level | $0.41 | $1.63 |
| Resistance Level | $1.18 | $5.08 |
| Average True Range (ATR) | 0.07 | 0.61 |
| MACD | -0.01 | -0.22 |
| Stochastic Oscillator | 21.36 | 9.51 |
Price Performance
Historical ComparisonAbout DFLI Dragonfly Energy Holdings Corp. (NV)
Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.